PEPFAR and Gilead Collaborate to Expand HIV Prevention with Breakthrough Drug
TL;DR
The U.S. Department of State announced a PEPFAR initiative to bring Gilead Sciences' breakthrough HIV drug lenacapavir to high-burden countries, aiming to reach up to 2 million people by 2028. The twice-yearly injectable medication, which has shown over 99% effectiveness in clinical trials, will be distributed with the support of the U.S. government and the Global Fund, at no profit from Gilead, to help prevent mother-to-child transmission and reduce HIV infections globally.
- PEPFAR’s Support of American Innovation to Reach up to 2 Million People by 2028 with Breakthrough HIV Drug Lenacapavir U.S. Department of State (.gov)
- Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug NPR
- Trump administration to help share new HIV drug with impacted nations The Washington Post
- Trump administration confirms plan for PEPFAR to distribute Gilead's new HIV prevention drug statnews.com
- Gilead Sciences advances HIV prevention with new US partnership Yahoo Finance
Want the full story? Read the original reporting
Read on U.S. Department of State (.gov)